Fri, Jul 25, 2014, 8:29 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Array BioPharma, Inc. Message Board

  • tuna_20_25 tuna_20_25 Oct 22, 2013 9:23 AM Flag


    5 Million milestone payment, potentially up to 70 million in milestone payments AND
    AstraZeneca began a pivotal trial with Array-invented selumetinib in patients with thyroid cancer in August 2013 and began a Phase 3 trial in patients with non-small cell lung cancer in October 2013. Two other wholly-owned drugs, ARRY-520 and ARRY-614, are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.

    4 drugs in Phase 3 before year end and training @ 5.00 ? A STEAL at these levels IMO

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • burnaka Oct 22, 2013 12:08 PM Flag

      Appears the market did not care or barely noticed the news. It is only a 5 million payment, a drop in the bucket given their 90 million cash burn rate. Most stocks spike on a phase 3 announcement Arry a yawn because it is licensed out, as such they are giving away most of the potential profits. Azn got a little pop though.

      Phase 3 drugs are great, and Arry has two more potential phase 3 by years end, yawn, this is nice, phase 3 to market is still 2-3 years off IF a drug meets study goals. Arry has enough cash to last ONE year, so another bond or LIKELY stock offering is due mid 2014, this will keep a lid on share price.

      So no rush to load the boat on Arry it is looking like 2016 before any real cash flow. I think it could more than double but not until successful completion of one of these phase 3 studies. Prior to that point given the tiny market cap Arry will be a buy out target given the over billion in owed milestone/royalty packages. Royalties possible Genentec = 685m, Novartis = 408m. Genentec or Novartis would likely buy Arry rather than pay theroyalties

      Just my take, Long a small initial stake in arry, and hoping for the November dip below 5.00 to add.

4.18-0.10(-2.34%)Jul 25 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.